Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avicena has reported that the Research Center at Columbia University has completed enrollment for a new type of study to assess Avicena's treatment for amyotrophic lateral sclerosis.
Subscribe to our email newsletter
In this phase II trial, investigators will assess the efficacy, safety and tolerability of Avicena's ALS-08 drug candidate in separate combinations with two treatments, minocycline and celecoxib.
The study design uses a two-stage protocol to determine a superior combination drug candidate. Following treatment, investigators will assess the mean difference in the two treatments. After trial completion, the superior combination therapy will be selected for further study in a phase III clinical trial.
“The unique study design allows for an effective assessment of the neuron-protective potential of ALS-08 in combination with two separate agents that have shown to influence different mechanisms of neurodegeneration,” said CEO Belinda Tsao-Nivaggioli.
Investigators will also assess whether the combination drug candidates are safe and well tolerated in conjunction with riluzole, the only FDA-approved ALS drug.